

# Bioheart, Inc. is Recipient of Prestigious South Florida Business Journal Technology Award for 2001

---



On the cutting edge in medicine.



Bioheart, Inc. Technology  
Award Winner 2001

**B**ioheart was founded in 1999 to provide development and commercialization of cellular-based therapy products in the treatment of cardiovascular diseases, including myocardial infarction, congestive heart failure and angina pectoris.

“We expect to lead the way in utilizing cellular-based therapies to repair damaged and weakened heart muscles,” said Howard Leonhardt, CEO and chairman of the company.

Leonhardt said heart disease is the leading killer in the world, and despite all advances made in the last century, mortality has barely dropped.

“In the United States alone, 5 million heart failure patients, 7 million myocardial infarction patients, 6 million angina pectoris patients, and 50,000 heart transplant candidates could potentially benefit from the

technology, the first year that it is fully available; after controlled studies are completed.” Leonhardt said. “We believe using cells to regenerate damaged heart muscles, which should prevent and reverse heart failure, could have a greater impact on saving human life than any single development ever. We have cautious hope for this now during early stage clinical trials.”

The company, founded in 1999 with four employees, had no income and lost almost \$1 million that first year. For fiscal 2001, the company has grown to 35 employees and has projected revenues of \$1.5 million but will lose \$7 million.

For the treatment of a continuum of cardiovascular disease ranging from heart attack to end-stage heart disease, Bioheart is developing a cell transplantation technology to regenerate functioning muscle in what was previously infarcted or scarred myocardial tissue.


Multiple cell types have been used by researchers to attempt cardiac repair, including fetal cardiomyocytes, autologous skeletal myoblasts, smooth muscle cells, immortalized myoblasts, fibroblasts, adult cardiac derived cells, embryonic stem cells and bone marrow-derived stromal cells.

“Our company believes that its products hold the **potential** to revolutionize the treatment of cardiovascular diseases and become a new standard of care by offering treatments to patients that are improved, more cost-effective and lower-risk than current alternatives, such as heart transplant, biventricular pacing, ventricular assist devices and certain drug therapies,” Leonhardt said.

Leonhardt, founder of Bioheart, also founded World Medical Manufacturing in 1986. World Medical produced cardiovascular balloon catheters and stent grafts for aortic aneurysm repair. Leonhardt is the inventor, with patents and patents pending on nearly a dozen cardiovascular related devices. He invented the TALENT (Taheri-Leonhardt) stent graft system working in cooperation with Dr. Syde Taheri.

Bioheart  
**CEO/Chairman:**  
Howard Leonhardt  
**Web site:**  
[www.bioheartinc.com](http://www.bioheartinc.com)  
**Address:** 2400 N.  
Commerce Parkway,  
Suite 408,  
Fort Lauderdale 33326  
**Phone:**  
(954) 217-7259

---



Howard Leonhardt, chairman and  
CEO of Bioheart in Fort Lauderdale.

---

winner: shooting stars

---